ArticleInternational journal of hematology2026
Salvage radiotherapy in refractory adult Hodgkin and non-Hodgkin lymphoma.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough Hodgkin and non-Hodgkin lymphoma are chemosensitive, 10-15% of patients develop refractory disease. With the increasing use of intensive chemotherapy, the role of radiotherapy (RT) in salvage settings has diminished. This study evaluated the efficacy of salvage RT in patients with refractory lymphoma. MATERIALS AND
methodsForty-one adults with histologically confirmed Hodgkin or non-Hodgkin lymphoma and either primary refractory or relapsed/refractory disease treated between 2010 and 2022 were retrospectively analyzed. All patients received involved-site RT after systemic therapy.
resultsAt a median follow-up of 67 months, 85% of patients showed a complete response to salvage RT and 10% showed a partial response. The 5- and 10-year disease-specific survival rates were 90 and 84%. All recurrences occurred within 5 years and outside the RT field.
conclusionSalvage RT achieved high response rates, durable survival, and minimal toxicity, supporting its role as a valuable treatment option in selected patients.
Indexed as
Identifiers
41593423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.